Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto
An EEG (electroencephalogram) is a test that measures electrical activity in the brain and is commonly used to diagnose seizures, stroke, and other neurological conditions.
Faced with a high volume of neuro-related transfers and limited access to specialty care, HMH leadership assembled a task force to study ER transfer patterns. "We looked at two years of transfer data and saw that many patients were being transferred for neuro-related issues, particularly when an EEG was needed," said Joe Schorre, Director of Cardiopulmonary and Emergency Management, who led the EEG implementation at HMH. "Our goal was to turn those transfers into local admissions."
Knowing that the EEG services were needed for Huntsville and Walker County, the hospital explored options for bringing neurological diagnostics in-house as part of a broader inpatient teleneurology and stroke program. The result was the successful implementation of a rapid EEG solution from Zeto that requires no gels or pastes and can be set up by respiratory therapists in under five minutes. "We're not EEG techs, so we needed a solution that was easy to learn, easy to apply, and could integrate with remote neurologists for interpretation," said Schorre.
Since the program's launch in December 2024, HMH has been able to admit more than 40 patients who would otherwise have been transferred to a facility over 30 miles away at a minimum. "Having the ability to implement an EEG program here at HMH is huge step forward for us to elevate the level of care for Walker County residents. Receiving high quality services closer to home which means families and loved ones don't have to travel, lose time from work, or worry about being separated from loved ones during treatment," Patrick Shannon, CEO of HMH stated. "For many in our rural community, that makes a huge difference."
The program has also supported the development of an outpatient EEG program, allowing local primary care providers to refer patients for pre-neurology diagnostic testing. "We're helping patients get their EEG and MRI here, so by the time they go to the neurologist, they have data in hand," said Schorre. "It shortens the wait time and gets them the care they need faster."
Looking ahead, HMH plans to expand services into continuous EEG monitoring and outpatient teleneurology. "This is about doing what's right for our community. We don't have local neurology, but we do have smart, committed staff and the tools to support them," said Schorre.
About Huntsville Memorial HospitalHuntsville Memorial Hospital, Huntsville, Texas, is currently a 123-bed, CIHQ‐accredited, not‐for‐profit acute care community hospital. HMH delivers quality healthcare services to the residents of Walker County and its surrounding communities, a population of more than 82,000. HMH and its dedicated staff offer compassionate care and the latest technologies and treatment solutions. HMH holds the American Heart Association Primary Stroke Center designation. HMH keeps community health and wellness at the forefront of its mission. Please visit us at www.huntsvillememorial.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/huntsville-memorial-hospital-reduces-patient-transfers-and-enhances-local-care-with-onsite-eeg-program-powered-by-zeto-302478575.html
SOURCE Zeto, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
DexCom Expands Access and Innovation While Balancing Headwinds
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research Short-Term Growth Drivers U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management's confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom's over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom's competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Long-Term Growth Drivers Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM's clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom's G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom's innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a 'consumer technology mindset,' rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Challenges Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom's business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Competition Update Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % — beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche's potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic's Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic's MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Conclusion DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company's leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
USA Today
2 hours ago
- USA Today
Deadly NYC Legionnaires' disease outbreak fueled by negligence, lawsuit says
Civil rights attorney Ben Crump has filed lawsuits against two construction companies over what he called a "completely preventable" outbreak of Legionnaires' disease that has killed five people and sickened more than 100 others in New York City. Legionnaires' disease is a severe pneumonia caused by a type of bacteria called Legionella, which grows in warm or hot water, according to the Centers for Disease Control and Prevention. An outbreak of the disease, which began on July 25, has been clustered across five zip codes in Central Harlem. The city health department said the outbreak is linked to cooling towers, heat exchangers that use fans and water to cool down buildings. On Aug. 14, health officials confirmed that 12 cooling towers at buildings including NYC Health + Hospitals/Harlem tested positive for the Legionella bacteria. Crump and other attorneys filed complaints on behalf of two construction workers who were hospitalized with Legionnaire's disease in July after working near the hospital in Harlem, according to a news release. Crump said the legal team has also filed a notice of claim and intend to sue the city as well. "It is believed that the cooling towers at Harlem Hospital were filled with rainwater after several large July storms," the release said. "The water was left untreated, which permitted bacteria to spread causing workers at the site to become sick." Construction companies, city accused of negligence Crump accused Skanska USA Building, Inc., Rising Sun Construction LLC and the city of negligence at a news conference on Aug. 20, announcing the lawsuits. The attorneys said the construction companies were put on notice about the possibility of Legionella bacteria through bulletins after the storms, but failed to take action to keep those working near the hospital safe. "When corporations cut corners, tragedies like this happen. Preventable tragedies, unnecessary tragedies," Crump said. Crump said the lawsuit is seeking not only compensation for the workers but also accountability and answers about why this outbreak occurred in Harlem — a historically Black neighborhood in Upper Manhattan. Skanska and Rising Sun did not immediatedly respond to a request for comment from USA TODAY. When asked about Crump's claims about the source of the outbreak, a spokesperson for the city's health department said the investigation is ongoing. "Molecular testing may help us determine which cooling tower — or cooling towers — were the source of the bacteria in the Central Harlem cluster," spokesperson Chantal Gomez said in a statement. "The Public Health Lab is still determining a match through DNA sequencing and we expect final results soon.' Electrian describes gasping for air while hospitalized with Legionnaire's Nunzio Quinto, a union electrian who worked at a ground-up construction of the NewYork City Public Health Laboratory, a 10-story facility adjacent to the hospital complex, said he thought he had food poisoning when he first started feeling lethargic in late July. Quinto said his family took him to the hospital, where he was immediately diagnosed with Legionnaire's disease. He suffered breathing problems, pain and internal bleeding during a five-day stay in the hospital, but said his coworkers weren't notified of his illness. "I want answers to what's going on. I can't have a safe place to work? This is New York City," Quinto said at the news conference. Contributing: Thao Nguyen
Yahoo
2 hours ago
- Yahoo
Global Healthcare Gets a 6G Boost: Market to Grow at 77.9% CAGR Through 2040
"This report explores how 6G is poised to reshape global healthcare through innovations in remote patient monitoring, AR/VR diagnostics, robotic surgeries, and smart hospital infrastructure, powered by ultra-low latency, AI integration, and massive device connectivity." BOSTON, Aug. 20, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "6G in Healthcare: Global Market" is projected to reach $194 billion by the end of 2040 with a CAGR of 77.9% from 2031 to 2040. The report analyzes the global 6G market in healthcare, exploring trends, challenges, and growth drivers. It segments the market by component, application, connectivity, end user, and region, covering the major areas of North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Additionally, it evaluates the competitive landscape by ranking leading companies and profiling major players. This report is especially relevant now as the global momentum toward digital healthcare transformation continues to grow, and research into 6G technology rapidly advances. It provides timely insights into how 6G is poised to revolutionize healthcare by enhancing delivery, boosting efficiency, and driving innovation. For early adopters and stakeholders, understanding these developments is crucial to staying ahead in a highly competitive and evolving landscape. The factors driving the market's growth include: Rising Demand for Enhanced Healthcare Services and Efficiency: Healthcare systems are under pressure to deliver faster, more personalized, and cost-effective care. 6G can support this by enabling real-time diagnostics, AI-powered decision-making, and seamless telemedicine experiences, ultimately improving service quality and operational efficiency. Growing Adoption of IoT and Connected Devices in Healthcare: The increasing use of wearables, smart medical equipment, and remote monitoring tools is transforming healthcare. 6G will enhance these technologies by offering faster data transmission, better connectivity, and improved energy efficiency, creating a smarter and more responsive healthcare ecosystem. Need for Ultra-Reliable and Low-Latency Communication for Critical Applications: In life-critical scenarios like remote surgeries or emergency response, reliability and speed are essential. 6G's ultra-low latency and high reliability ensure uninterrupted, secure communication, making it ideal for mission-critical healthcare applications. Request a sample copy of the global market trends for 6G in healthcare report. Report Synopsis Report Metric Details Base year considered 2030 Forecast period considered 2031-2040 Base year market size $664.2 million Market size forecast $194.0 billion Growth rate CAGR of 77.9% from 2031 to 2040 Segments covered Component, Application, Connectivity Type, End User, and Region Regions covered North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) Countries covered U.S., Canada, Mexico, Brazil, Argentina, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Rest of Europe, the Middle East, and Africa Market drivers • Rising demand for enhanced healthcare services and efficiency. • Growing adoption of IoT and connected devices in healthcare. • Need for ultra-reliable and low-latency communication for critical applications. Interesting facts: 6G technology is expected to be 100 times faster than 5G, enabling real-time remote surgeries, seamless medical data transmission, and continuous biometric streaming via wearables for predictive healthcare analytics. It will also support digital twins, the virtual patient models that allow doctors to simulate treatments before applying them in real life. The integration of AI and 6G could dramatically reduce emergency response times through intelligent, connected systems. South Korea and China are among the countries already investing in national initiatives to lead 6G healthcare innovations by 2030. The report addresses the following questions: 1. What are the projected size and growth rate of the market? The global market for 6G in healthcare is projected to reach $194 billion by the end of 2040, with a CAGR of 77.9%. 2. Which factors are driving the growth of the market? The growth of 6G in the healthcare market is driven by increasing demand for real-time patient monitoring and data-intensive applications. Advances in AI and IoMT are enhancing diagnostic precision and care delivery through ultra-fast connectivity. The rising adoption of telehealth and remote surgeries requires the low latency and high reliability that 6G offers. Growing investments in smart hospitals and digital infrastructure further propel the market expansion for 6G. 3. Which market segments are covered in the report? The market in this report is segmented by component, application, connectivity, and end user. 4. Which component segment will be dominant through 2040? The hardware segment will dominate the market for 6G in healthcare. 5. Which region has the highest market share? The North America market for 6G in healthcare was valued at $201.3 million in 2030 and is projected to reach $52.6 billion in 2040, at a CAGR of 76.0% during the forecast period. Market leaders include: APPLE AT&T CISCO SYSTEMS HUAWEI TECHNOLOGIES CO. LTD. INTEL MICROSOFT NOKIA QUALCOMM TECHNOLOGIES INC. SAMSUNG SIEMENS HEALTHINEERS AG Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio
